垂体光子计数探测器CT用于库欣病:术前病灶定位、术中所见与术后结局
本研究纳入25例术前接受光子计数探测器CT(PCD-CT)并经蝶窦手术治疗库欣病的连续患者,对比增强MRI准确定位56%病灶,动态增强PCD-CT准确定位92%(P = .01),术后早期生化缓解率88%,随访时84%仍维持缓解。
要点
- 动态增强PCD-CT病灶定位准确率92%,高于对比增强MRI的56%(P = .01)。
- MRI阴性者占24%、误导者占20%;PCD-CT阴性者占4%、误导者占4%。
- 术后早期生化缓解率88%,随访时84%仍维持缓解。
核心结论
- PCD-CT在库欣病腺瘤定位中具有较高的术中确认率,即使在MRI阴性病例中亦然,可能带来较高的缓解率与腺体保留率。
研究设计与样本
- 单中心连续病例队列,2023年9月至2025年1月纳入25例库欣病患者,术前均行钆增强垂体MRI与PCD-CT,以术中直视、病理确认及术后生化缓解联合确认病灶位置为参考标准。
关键影像表现/征象
- 对比增强MRI准确定位56%病灶,阴性24%,误导20%。
- 动态增强PCD-CT准确定位92%病灶,阴性4%,误导4%(P = .01)。
诊断标准与关键数值
- 病灶定位准确性以术中直视、病理确认及术后生化缓解联合确认的病灶位置为参考标准。
- 对比增强MRI准确定位56%、阴性24%、误导20%。
- 动态增强PCD-CT准确定位92%、阴性4%、误导4%(与MRI比较P = .01)。
临床应用与阅片要点
- 作者认为PCD-CT在病灶定位方面有价值,尤其在MRI阴性病变中。
- PCD-CT在库欣病术前评估临床流程中的作用需进一步研究。
局限性
- PCD-CT在库欣病术前评估临床流程中的作用需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: MRI fails to localize a tumor in up to 40% of cases of adrenocorticotropic hormone-dependent Cushing disease (CD), impacting patient outcomes and creating uncertainty in the diagnosis. Photon-counting detector CT (PCD-CT) is a new CT technology with better imaging performance than conventional CT. PCD-CT is a novel imaging technique for CD, especially for MR-negative cases, however, its application to CD remains unknown.
MATERIALS AND METHODS: We present a cohort of consecutive patients with a preoperative PCD-CT undergoing transsphenoidal surgery for CD at a single institution from September 2023 to January 2025. All patients underwent gadolinium-enhanced pituitary MRI for baseline work-up and PCD-CT as part of their preoperative planning imaging. Both imaging modalities were used to localize the lesion and guide surgical planning. The accuracies of MRI and PCD-CT were based on confirmation of the lesion location by a combination of intraoperative visualization, pathologic confirmation, and postoperative biochemical remission, and were compared with each other via Fisher exact test.
RESULTS: Twenty-five patients with CD were included in this analysis. The cohort's median age was 50 years old, and 88% were women. At diagnosis, 88% had central obesity, 76% had hypertension, 48% had type 2 diabetes mellitus, and 20% had osteoporosis. Contrast-enhanced MRI accurately identified 56% of lesions, while it was negative in 24% and misleading in 20%. Dynamic contrast-enhanced PCD-CT was superior in localizing CD (P = .01), accurately identifying 92% of lesions, while it was negative in 4% and misleading in 4% of cases. Early postoperative biochemical remission was achieved in 88% of cases, while 84% remained in remission at follow-up.
CONCLUSIONS: PCD-CT had a high rate of adenoma localization confirmed intraoperatively, even among MR-negative cases, potentially leading to high remission and gland preservation rates. Its role in the clinical workflow of preoperative evaluation for CD requires further investigation, but current evidence supports its value in lesion localization, especially in MR-negative disease.
引用
- Mark IT, Michalopoulos G, Van Gompel J, et al. Pituitary Photon-Counting Detector CT for Cushing Disease: Preoperative Lesion Localization, Intraoperative Findings, and Postoperative Outcomes. AJNR Am J Neuroradiol. 2025. PMID: 40550699. doi:10.3174/ajnr.A8893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。